However, CM treatment decreased the FABP1 proteins in the hepatic, cardiac, and renal tissues (p < 0.0001, p = 0.0003, and p = 0.007, respectively) of the NAFLD+CM group in comparison to the NAFLD group. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.